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Abstract
Background: Coagulase-negative staphylococci (CoNS) are a major cause of nosocomial blood
stream infection, especially in critically ill and haematology patients. CoNS are usually multidrug-
resistant and glycopeptide antibiotics have been to date considered the drugs of choice for
treatment. The aim of this study was to characterize CoNS with reduced susceptibility to
glycopeptides causing blood stream infection (BSI) in critically ill and haematology patients at the
University Hospital Tor Vergata, Rome, Italy, in 2007.
Methods: Hospital microbiology records for transplant haematology and ICU were reviewed to
identify CoNS with elevated MICs for glycopeptides, and isolates were matched to clinical records
to determine whether the isolates caused a BSI. The isolates were tested for susceptibility to new
drugs daptomicin and tigecycline and the genetic relationship was assessed using f-AFLP.
Results: Of a total of 17,418 blood cultures, 1,609 were positive for CoNS and of these, 87 (5.4%)
displayed reduced susceptibility to glycopeptides. Clinical review revealed that in 13 cases (7 in
haematology and 6 in ICU), CoNS with reduced susceptibility to glycopeptides were responsible
for a BSI. Staphylococcus epidermidis was the causative organism in 11 instances and Staphylococcus
haemolyticus in 2. The incidence of oxacillin resistance was high (77%), although all isolates remained
susceptible to linezolid, daptomycin and tigecycline. Fingerprinting of CoNS identified one clonal
relationship between two isolates.
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Conclusion: Multi-resistant CoNS with reduced susceptibility to glycopeptides, although still
relatively infrequent in our hospital, are emerging pathogens of clinical concern. Surveillance by
antibiotyping with attention to multi-resistant profile, and warning to clinicians, is necessary.
Background
Coagulase-negative staphylococci (CoNS) are normal
commensals of the skin, anterior nares, and ear canals of
humans. They have long been considered as nonpathoge-
netic, and were rarely reported to cause severe infections.
However, as a result of the combination of increased use
of intravascular devices and an increase in the number of
hospitalized immunocompromised patients, CoNS have
emerged as a major cause of nosocomial bloodstream
infections [1-3].
CoNS, primarily Staphylococcus haemolyticus and Staphylo-
coccus epidermidis, are often resistant to multiple antibiot-
ics, and glycopeptides have been considered the drugs of
choice for the management of infections caused by these
organisms [4,5]. However, widespread use of glycopep-
tides recently has led to the emergence of CoNS isolates
with decreased susceptibility to glycopeptides, displaying
a minimal inhibitory concentration (MIC) of 4–8 mg/L
for vancomycin and/or a MIC of 8–16 for teicoplanin [6-
8]. Although acquired resistance to glycopeptides was first
documented in CoNS in 1986 [9], attention was focussed
on glycopeptide resistance in enterococci [10,11], due in
large part to the historically relatively infrequent occur-
rence of CoNS infections.
In the late 1990s, the emergence of glycopeptides resistant
Staphylococcus aureus in Japan [12] and in the USA [13]
and later reports on hetero-resistance to glycopeptides in
MRSA [14,15] raised the issue of the limited therapeutic
options remaining for these Gram positive multi-resistant
bacteria that largely cause nosocomial infections. The
extensive clinical isolation of multi-resistant CoNS, espe-
cially from blood, poses similar clinical concerns and
challenges.
At the University Hospital of Tor Vergata, Rome, Italy,
CoNS are most frequently isolated from blood cultures
taken from haematologic patients and from critically ill
patients admitted to the intensive care unit (ICU). Occa-
sionally, these CoNS isolates display a reduced suscepti-
bility to glycopeptides. Since the majority of these isolates
can be considered as contaminant, the incidence of CoNS
with reduced sensitivity to glycopeptides actually causing
bloodstream infections (BSI) is difficult to determine. The
objective of this study was to investigate whether glyco-
peptide-resistant CoNS represent a significant clinical
concern by examining CoNS isolates and patient records
for 2007. The second aim was to determine whether the
infecting bacteria were clonally related and to review the
therapeutic options.
Methods
This study was approved by local Ethical Committee (Uni-
versity of Rome – Polyclinic Tor Vergata) on march 2008.
We reviewed University Hospital Tor Vergata laboratory
records in 2007 to identify any CoNS isolated from blood
having a minimal inhibitory concentration (MIC) of ≥ 2
μg/mL for vancomycin and/or an MIC of ≥ 8 μg/mL for
teicoplanin. The search was limited to the transplant hae-
matology ward and the ICU where patient and clinical
data are routinely collected in a local database in which
every infective event is catalogued. All clinical isolates
were registered and stored at -80°C in defibrinated bovine
blood. Only non-duplicate blood stream isolates
included in the analysis.
We obtained information on the clinical course and out-
come, microbiological outcome, any antecedent use of
antimicrobial agents and actual therapy for each patient
who had a blood stream infection with a CoNS with
reduced susceptibility to glycopeptides.
Criteria used to categorize isolates as contaminants versus
blood stream infection were the following:
1) fever or signs of sepsis at the time of blood culture;
2) isolation of the same potential skin contaminant
from two or more blood cultures drawn on separate
occasions within a 48-hour period AND isolated from
a patient with an intravascular access device inserted at
least 48 hours before AND physician institutes appro-
priate antimicrobial therapy;
3) absence of any other possible site of infection;
To define whether an infection was catheter-related, one
of the following criteria had to be satisfied:
1) catheter tip was positive for the same agent
retrieved at a peripheral vein
2) blood culture drawn from catheter hubs revealed
the same agent isolated from peripheral vein but at
least 120 minutes before the latter.BMC Infectious Diseases 2009, 9:83 http://www.biomedcentral.com/1471-2334/9/83
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All the infectious events were classified by an expert infec-
tivologist in the local database as the microbiology results
were obtained.
Laboratory methods
Biochemical identifications and antibiotic susceptibility
tests were performed using the VITEK 2 automated system
(bioMerieux) following the manufacturer's instructions.
Susceptibility to tygeciclin and daptomycin was tested
using the appropriate E-test (AB Biodisk) following the
manufacturer's instructions. The strains were first induced
to express glycopeptides resistance by culture on Vanco-
agar screen plate, according to the Clinical and Laboratory
Standards Institute (appendix B) and CDC guidelines,
containing 6 μg/mL of vancomycin [16,17]. Then they
were tested with authomated system as well as by E-test.
The MIC (μg/mL) interpretative standard for vancomycin
and teicoplanin were those suggested by EUCAST (respec-
tively: ≤ 4 susceptible, ≥ 8 resistant).
Amplified Fragment Length Polymorphism
The genetic relationship among the isolates was deter-
mined by fingerprinting using the commercial kit f-AFLP
Microbial fingerprinting (Applera; Foster City, California)
according to the manufacturer's instructions using as
primers: AFLP primer MseI-CC, MseI-CG and AFLP FAM
primer EcoRI-O. The f-AFLP reactions were loaded and
run on the ABI 310 DNA genetic analyzer (Applera). Each
f-AFLP reaction was analysed using Genescan software
and Genographer program version 1.6.0 (kindly provided
by James J. Benham, http://hordeum.oscs.montana.edu/
genographer; Copyright C 1999 Montana State Univer-
sity). Cluster analysis was performed using the
unweighted pair group method with the averages algo-
rithm (UPGMA) [18]. The percentage similarity between
patterns was calculated using the Dice correlation coeffi-
cient [19].
Results
Patients and isolates
A total of 17,418 blood samples were screened in 2007,
14,195 from the transplant haematology ward and 3223
from ICU patients (Table 1). For the transplant haematol-
ogy samples, 1959 were blood culture-positive and of
these, 1383 (70.6%) yielded CoNS. Similarly, CoNS were
present in 47.3% (226/478) of culture-positive blood
samples from the ICU. Overall, using criteria defined in
the methods section, 92 out of 1609 CoNS positive blood
cultures (5.7%) were considered to be associated with
infection. Particularly in the transplant haematology ward
62 out of 1386 (4%) CoNS positive blood cultures caused
a BSI while in ICU, the BSI were 30 out of 226 CoNS iso-
lates (13%). In total, 87 CoNS isolates (69 S. epidermidis,
18 S. haemolyticus) displayed a reduced susceptibility to
glycopeptides, a frequency of 5.4%. Of these, 7 and 6 were
considered to be associated with infection in patients
from the transplant haematology ward and ICU, respec-
tively. Infections caused by CoNS with reduced suscepti-
bility to glycopeptides represent 11% and 20% of all
CoNS related BSI in haematology ward and ICU respec-
tively.
Clinical data for patients infected by CoNS with reduced
susceptibility to glycopeptides are presented in Tables 2
and 3. For transplant haematology patients, all had a cen-
tral vein device and were bone marrow transplant recipi-
ents (Table 2). Not all patients met the full criteria for
catheter related blood stream infection (CR-BSI). Never-
theless the infective event was classified as a blood stream
infection in the database. For all patients a combination
antimicrobial therapy was established according to the
therapy protocols of the ward. In all cases microbiology
eradication was reached. For ICU patients, all were being
treated for one other infection at the time of blood-cul-
ture, and all had a central vein device. In patient 9 it was
not possible to define whether the BSI was catheter related
because the patient died before completing the diagnosis.
In ICU the patients were treated with linezolid according
to susceptibility test. In all cases, except for patient 9 who
was not treated, microbiological eradication was
obtained. Overall, only 2 patients (patients 2 and 3, both
from the transplant haematology ward) had recorded pre-
vious exposure to glycopeptides.
The majority of isolates (11/13) were identified as S. epi-
dermidis, with the remaining two being S. haemolyticus,
both of which were isolated from transplant haematology
ward patients (Table 4). All isolates demonstrated reduced
sensitivity to vancomycin (MIC ≥ 2 μg/mL) whereas 7 iso-
lates demonstrated reduced sensitivity to teicoplanin
Table 1: Results of blood culture screening.
Blood cultures screened 
(no. positive)
Blood cultures yielding CoNS Strains with reduced susceptibility to 
glycopeptides
Total Associated with infection Total Associated with infection
Transplant haematology 
ward
14,195 (1959) 1383 62 76 7
ICU 3223 (478) 226 30 11 6BMC Infectious Diseases 2009, 9:83 http://www.biomedcentral.com/1471-2334/9/83
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(MIC ≥ 8 μg/mL). The MLSB phenotype, and resistance to
oxacillin (MIC ≥ 4 μg/mL) were widespread, each being
found in 10 (77%) isolates. All strains remained sensitive
to daptomycin, tigecycline and linezolid (Table 4). All
strains were also able to grow on Vanco-screen agar
according to CLSI algorithm. This means that subpopula-
tions in each strain grow in the presence of ≥ 6 mg/L of
vancomycin. Accordingly these strains display heterore-
sistance and may be associated with therapeutic failure.
The ratio of S. epidermidis to S. haemolyticus in the strains
associated with infection was 11/2 = 5.5. Overall, includ-
ing resistant CoNS considered to be contaminants, the
ratio S. epidermidis to S. haemolyticus was 69/18 = 3.8
There was no obvious trend in isolation of CoNS with
reduced sensitivity to glycopeptides across the year of
study (Fig. 1).
Genomic analysis
As shown by f-AFLP profile analysis (Fig. 2), the genetic
relatedness among the 13 isolates was low (overall simi-
larity <65%). Cluster analysis revealed two clusters corre-
sponding to transplant haematology ward isolates
(overall similarity approximately 70%) and ICU isolates
(overall similarity 73%). In the ICU-cluster, two isolates
(from patients 11 and 12) had a similarity of 95% and
were clonally related. The isolate from patient 11 was
retrieved in the month of august while the CoNS from
patient 12 was isolated in the month of November. The
two patients were admitted and confined in bed in differ-
ent periods.
Discussion
All the patients were at increased risk for the development
of CoNS infections for different reasons. Patients from the
transplant haematology ward were neutropenic or were
Table 2: Characteristics of patients from transplant haematology ward infected with CoNS displaying reduced susceptibility to 
glycopeptides
Pat. Age Underlying 
disease
Antimicrobial 
prophylaxis
Neutrophyl 
count/mm3
Days from 
transplantation
Immuno-
suppression
Therapy Catheter 
removal
CR-BSI Micro-
biological 
eradication
1 29 ALL no 2300 43 ciclosporin linezolid-pip/
tazo-amika
no ? yes
2 40 MM no 1380 128 ciclosporin teicoplanin-pip/
tazo-amika
no ? yes
3 34 AML levofloxacin 10 9 no linezolid-pip/
tazo-amika
yes yes yes
4 20 HD no 6200 3 no teicoplanin-pip/
tazo-amika
no ? yes
5 52 NHL levofloxacin 10 5 no teicoplanin-pip/
tazo-amika
yes yes yes
6 54 ALL no 1000 3 ciclosporin teicoplanin yes yes yes
7 58 MM no 3700 30 no teicoplanin-pip/
tazo-amika
yes yes yes
ALL = acute lymphocitic leukaemia; AML = acute myeloid leukaemia; MM = multiple myeloma; HD = Hodgkin's disease; NHL = non-Hodgkin's lymphoma; MUD = matched 
unrelated donor; pip/tazo = piperacillin/tazobactam; amika = amikacin; CR-BSI = catheter related blood stream infection; ? = not confirmed
Table 3: Characteristics of patients from ICU infected with CoNS displaying reduced susceptibility to glycopeptides.
Patient Age Diagnosis on 
admission
Therapy on day of 
blood cultures
CR-BSI Catheter removal Treatment Micro-biological 
eradication
85 9 Pseudomonas aeruginosa 
pneumonia
piperacillin/tazobactam + 
claritromicin + 
teicoplanin
yes yes linezolid yes
9 83 Abscess of psoas piperacillin/tazobactam + 
metronidazole + 
teicoplanin
?n on o n e ?
10 53 Post neurosurgery 
cerebral abscess
meropenem + teicoplanin yes yes linezolid yes
11 59 MDR P. aeruginosa 
pneumonia
meropenem ? no linezolid yes
12 85 Acinetobacter baumannii 
pneumonia
colimicin yes yes linezolid yes
13 66 Sepsis from infected 
flebitis in multiple trauma 
patient
fluconazole yes yes linezolid yes
CR BSI = catheter related blood stream infection; ? = not confirmedBMC Infectious Diseases 2009, 9:83 http://www.biomedcentral.com/1471-2334/9/83
Page 5 of 8
(page number not for citation purposes)
Table 4: Characteristics of CoNS clinical isolates associated with infection.
Pat Species MIC VAN MIC TEIC MLSB phenoptype MIC OXA MIC DAP MIC TIG MIC LZD
Transplant haematology ward isolates
1 S. epidermidis 2 2 yes 4 0.023 0.047 2
2 S. epidermidis 2 4 yes 0.5 0.047 0.047 1
3 S. epidermidis 2 4 yes 4 0.094 0.064 1
4 S. haemolyticus 2 8 yes 4 0.125 0.047 2
5 S. epidermidis 2 4 no 0.25 0.047 0.032 1
6 S. haemolyticus 2 8 yes 4 0.064 0.047 2
7 S. epidermidis 4 16 no 0.25 0.125 0.047 2
ICU isolates
8 S. epidermidis 2 4 yes 4 0.023 0.047 1
9 S. epidermidis 21 6 y e s 4 0 . 0 4 7 0 . 0 4 7 2
10 S. epidermidis 4 ≥ 32 no 4 0.094 0.064 1
11 S. epidermidis 21 6 y e s 4 0 . 1 2 5 0 . 0 4 7 2
12 S. epidermidis 21 6 y e s 4 0 . 0 6 4 0 . 0 4 7 1
13 S. epidermidis 2 4 yes 4 0.047 0.032 2
MIC values are presented as μg/mL. VAN = vancomycin; TEIC = teicoplanin; MLSB = resistance to macrolides, lincosamides and type B 
streptogramins; OXA = oxacillin; DAP = daptomycin; TIG = tigecycline; LZD = linezolid.
Isolation frequency by month of CoNS strains with reduced susceptibility to glycopeptides in 2007 Figure 1
Isolation frequency by month of CoNS strains with reduced susceptibility to glycopeptides in 2007. Data are pre-
sented for all isolates; the 13 isolates deemed to be associated with infection are indicated by asterisks. Blue asterisks indicate 
clonal relationship.
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receiving immunosuppressant drugs, while patients from
the ICU were critically ill and were being treated with
broad spectrum antibiotics for different infections. Impor-
tantly, they all had a central vein catheter. One observa-
tion of concern is that only two of the thirteen patients
had previous exposure to glycopeptides. This is in contrast
to other reports describing the selection of resistance after
exposure to vancomycin or teicoplanin in CoNS [8,20]. In
the current study, the great number of CoNS isolated from
blood were considered to be contaminants, particularly in
the haematology ward where blood cultures are drawn for
routine for surveillance other than to diagnose infection.
In this ward therapy protocols schedule an association of
antimicrobials on signs of infections. This may lead to
underestimate the frequency of CR-BSI interfering with
cultures. In ICU blood cultures are drawn on signs of
infection, so the number of clinically relevant CoNS out
of the total amount of blood cultures is higher, although
the level of contamination is also high. It can be very dif-
ficult to draw blood from venipuncture in haematology or
critically ill patients, so a certain level of contamination is
probably unavoidable, but our data impose to be more
strict in sending in blood for cultures in order to limit false
positive cultures that may lead to overtreatment.
Our data support the idea that CoNS with reduced suscep-
tibility to glycopeptides are endemic in these wards and
are maybe resident on skin and nares of personnel and
patients. Indeed, genomic analysis revealed that different
strains were responsible for most infections. Only two iso-
lates displayed a clonal relationship. As a direct contact
between the two patients was excluded, ward or personnel
contamination should be implicated. Nevertheless, as far
as we are aware, there is no indication for screening and
decontamination of CoNS in patients and personnel from
critical areas such as the haematology ward and the ICU.
This could be an issue for further studies.
After this study, the actual therapy strategy in the two
wards is to start empirical treatment with glycopeptides if
CR-BSI is suspected and promptly shift to a different drug
according to susceptibility test if the diagnosis is con-
firmed or if treatment fails. Nevertheless if the signs of
infection are severe or if clinical conditions do not allow
to wait, therapy with linezolid is started and eventually
de-escalated on sensitivity report.
The majority of isolates were S. epidermidis and this spe-
cies was slightly more frequently associated with BSI than
S. haemolyticus. It was widely accepted that S. haemoyiticus
is uniquely predisposed among CoNS to develop glyco-
peptides resistance as this was the first CoNS species in
which vancomycin and teicoplanin resistance was identi-
fied [21]. Nowadays S. epidermidis is often reported to be
a nosocomial pathogen bearing multi-resistance [22-24].
Moreover there are many studies suggesting the possible
relationship between methicillin resistance and reduced
susceptibility to glycopeptides in CoNS [9,25,26].
Not all clinical isolates demonstrated MICs for vancomy-
cin and teicoplanin in the intermediate susceptibility
range, but they were all shifted towards the cut-off level.
Moreover, these isolates were also able to grow on Vanco-
screen agar. It has been previously shown that staphyloco-
cci able to grow on Vanco-screen agar may display hetero-
resistance to glycopeptides [27]. Heteroresistance was first
defined as the presence of >10-6stable cell subpopulations
of a strain that is apparently susceptible to vancomycin on
the basis of conventional criteria, but for which the vanco-
mycin MIC for the subpopulation of cells is greater than
or equal to 8 mg/liter [12]. Since 2006 CLSI breakpoints
have changed, actual definition might be that although
the MIC for the entire population is within the range of
susceptibility according to the CLSI criteria, subpopula-
f-AFLP analysis of the genetic relatedness of CoNS isolates  with reduced susceptibility to glycopeptides Figure 2
f-AFLP analysis of the genetic relatedness of CoNS 
isolates with reduced susceptibility to glycopeptides.BMC Infectious Diseases 2009, 9:83 http://www.biomedcentral.com/1471-2334/9/83
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tions grow in the presence of ≥ 4 mg/L of vancomycin. The
hetero-resistant phenotype may be associated with treat-
ment failure and/or may be precursor of glycopeptide
resistance and should be considered in both empirical
and rational therapy decisions.
In our series, CoNS remained homogeneously susceptible
in vitro to linezolid, tigecycline and daptomycin. Of these
three drugs only daptomycin is suitable for the treatment
of BSI, given its pharmacokinetic profile. Linezolid was
used off label to treat most patients. The use of linezolid
for the treatment of catheter related Gram positive blood
stream infections is still a matter of discussion, as there
have been suggestions that it is associated with a higher
mortality rate depending on the type of infection [28].
Nevertheless, in a recent cohort study, empiric therapy
with linezolid was associated with greater survival and
more successful microbiological eradication compared to
standard therapy in the treatment of methicillin-resistant
S. aureus bacteremia [29]. Further, in a pharmacoeco-
nomic evaluation study linezolid was considered more
efficient than teicoplanin in the treatment of Gram-posi-
tive bacteremia [30].
Tigecycline is not registered for the treatment of bactere-
mia, and its use should be limited to real clinical necessity
to preserve its activity against multi-resistant Gram nega-
tive bacteria. Clinical efficacy of daptomycin has been
demonstrated in patients with S. aureus bacteremia [31].
To our knowledge no clinical data exist on daptomycin
efficacy against CoNS with elevated MICs for glycopep-
tides. A remarkable characteristic related to low-level
resistance to glycopeptides in CoNS is cell wall thickness
[27]. Due to its mechanism of action, this characteristic
may interfere with daptomycin also, at least in clinical set-
ting or subsequent to extensive use.
Conclusion
In conclusion, although still relatively infrequent, mul-
tiresistant CoNS with reduced susceptibility to glycopep-
tides are emerging pathogens of clinical concern and
should be kept in mind both in empirical and rational
therapy of CR-BSI. Surveillance by antibiotyping with
attention to multi-resistant profile is mandatory and
warning to clinicians is also necessary. Genotyping analy-
sis are useful to discern an epidemic outbreak, which
should lead to the implementation of behavioural modi-
fications and, potentially, decontamination may be con-
sidered.
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